

RESEARCH MONOGRAPH . COMPOUND PROFILE

Procyanidin C1

A naturally occurring epicatechin trimer from grape seed extract identified as a dual-mode senotherapeutic agent that selectively eliminates senescent cells at high concentrations while suppressing the senescence-associated secretory phenotype at low concentrations, with demonstrated lifespan extension in mice and emerging preclinical evidence across fibrotic, neurodegenerative, and oncologic indications.

DOCUMENT	KDC-MN-1573
ISSUED	2026-05-20
REVISION	1.0
AUTHOR	Kodiac bioLabs Research
COMPOUND CLASS	B-type proanthocyanidin trimer (oligomeric flavan-3-ol) with senolytic, senomorphic, and multi-target anti-inflammatory activity

ABSTRACT

Procyanidin C1 (PCC1) is a B-type proanthocyanidin trimer composed of three (2R,3R)-(-)-epicatechin units joined by two successive (4beta to 8)-interflavan bonds, with molecular formula C₄₅H₃₈O₁₈ and molecular weight 866.77 g/mol. The compound is a polyphenolic constituent of grape seed extract (GSE), cocoa, cinnamon bark, unripe apple peel, and pine bark, and was first structurally characterized in the 1980s as part of the broader oligomeric proanthocyanidin (OPC) family originally described by Masquelier in 1947. PCC1 remained a minor analytical curiosity within the proanthocyanidin literature until 2021, when a landmark screening study by Xu, Fu, and colleagues, published in *Nature Metabolism*, identified PCC1 as a potent and selective senotherapeutic agent capable of extending healthspan and lifespan in aged mice through dual-mode activity on senescent cells [1]. At low concentrations (below approximately 50 micromolar), PCC1 acts as a senomorphic agent, suppressing the production of pro-inflammatory senescence-associated secretory phenotype (SASP) factors through inhibition of NF-kappaB signaling without inducing senescent cell death. At higher concentrations (above approximately 100 micromolar), PCC1 transitions to a senolytic mode, selectively inducing apoptosis in senescent cells through a reactive oxygen species (ROS)-dependent mitochondrial dysfunction pathway involving the p53-Puma/Noxa axis, while sparing proliferating and quiescent non-senescent cells. This concentration-dependent functional switch distinguishes PCC1 from most other characterized senolytic agents and provides a pharmacological basis for dose-titrated senotherapeutic intervention.

The 2021 Nature Metabolism study demonstrated that intermittent administration of PCC1 (20 mg/kg intraperitoneally, biweekly for two months) to aged C57BL/6J mice reduced senescent cell burden across multiple tissues, attenuated age-related physical dysfunction, and extended median remaining lifespan by approximately 64 percent compared to vehicle-treated controls, with no observed systemic toxicity [1]. Subsequent preclinical studies have expanded the evidence base substantially. Zhu, Huang, and colleagues (2024) demonstrated that PCC1 alleviates structural and functional decline in the aged mouse retina through combined senolytic and senomorphic mechanisms [2]. Gan and colleagues (2025) reported that PCC1 alleviates renal fibrosis by promoting apoptosis of senescent renal tubular epithelial cells [3]. Additional preclinical evidence supports activity against skin fibrosis through EGFR inhibition and TGF-beta/SMAD pathway suppression [4], neuroprotection through Nrf2/HO-1 signaling activation [5], endothelial nitric oxide production through PI3K/Akt-dependent eNOS phosphorylation [6], insulin sensitization in adipocytes through AKT-eNOS pathway activation [7], and colon cancer growth inhibition through miR-501-3p/HIGD1A axis modulation [8]. Single-cell profiling has revealed broad geroprotective effects on the hematopoietic immune system, including restoration of B cell and hematopoietic stem cell populations and suppression of senescence-associated inflammatory markers [9].

Pharmacokinetically, PCC1 shares the absorption limitations characteristic of oligomeric proanthocyanidins: oral bioavailability of trimeric procyanidins is low, with the majority of ingested material reaching the colon intact where it is degraded by gut microbiota into phenylvalerolactones, phenylvaleric acids, and smaller phenolic acid metabolites. Phytosomal formulations have

demonstrated 2- to 3-fold improvements in gastrointestinal absorption efficiency. No completed Phase 1 or Phase 2 clinical trials of purified PCC1 have been published as of the most recent monograph revision, though preliminary findings from phytosomal PCC1 formulations have shown reductions in senescence markers in peripheral blood mononuclear cells from elderly individuals. The compound is not approved by any regulatory authority for therapeutic use. It is available as a research-grade preparation from multiple chemical suppliers at greater than 95 percent purity by HPLC. This monograph documents the chemistry, natural sourcing, dual-mode senotherapeutic pharmacology, pharmacokinetics, preclinical evidence base across aging, fibrotic, neurodegenerative, metabolic, and oncologic indications, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event signal, and a structured comparative assessment of five senolytic candidates against PCC1 on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

Common name: Procyanidin C1.

Synonyms: Proanthocyanidin C1, Procyanidol C1, PCC1, (-)-Epicatechin-(4beta->8)-(-)-epicatechin-(4beta->8)-(-)-epicatechin.

Chemical Abstracts Service registry number: 37064-30-5.

International Union of Pure and Applied Chemistry name: (2R,2'R,2''R,3R,3'R,3''R,4R,4'S)-2,2',2''-tris(3,4-dihydroxyphenyl)-3,3',3'',4,4',4''-hexahydro-[4,8':4',8''-ter-2H-1-benzopyran]-3,3',3'',5,5',5'',7,7',7''-nonol.

PubChem CID: 169853.

ChEBI ID: ChEBI:75631.

UNII (FDA Substance Registration System): Not assigned as of monograph date.

1.2 Structural class and chemistry

Procyanidin C1 is a B-type proanthocyanidin trimer belonging to the oligomeric flavan-3-ol class of polyphenolic compounds. The structural class is defined by the presence of (4beta to 8)-interflavan bonds connecting three (-)-epicatechin monomer units in a linear chain. B-type proanthocyanidins are distinguished from A-type proanthocyanidins by the absence of the additional ether bond (C2-O-C7) that characterizes A-type linkages. The compound is a member of the broader condensed tannin family, which includes dimeric (B-series), trimeric (C-series), and higher oligomeric and polymeric proanthocyanidins.

Molecular formula: C₄₅H₃₈O₁₈.

Exact mass: 866.2060 g/mol (monoisotopic).

Molecular weight: 866.77 g/mol.

Physical properties: Amorphous off-white to light tan powder. Soluble in water, methanol, ethanol, dimethyl sulfoxide, and aqueous acetone; sparingly soluble in apolar organic solvents. The compound is hygroscopic and should be stored under desiccated conditions. Melting point is not sharply defined owing to the amorphous nature of the solid; thermal decomposition occurs above approximately 200 degrees Celsius.

Stereochemistry: Procyanidin C1 contains eight stereocenters across the three epicatechin subunits and the two interflavan bonds. The natural product has the (2R,3R) absolute configuration at each epicatechin unit (corresponding to (-)-epicatechin rather than (-)-catechin or (+)-epicatechin) and the (4R) configuration at each upper interflavan carbon with the (4beta to 8) regiochemistry. The compound is therefore a single stereoisomer as isolated from natural sources. Analytical confirmation of stereochemical integrity is appropriate when working with synthetic or semi-synthetic preparations, as epimerization at the interflavan bond can occur under acidic conditions.

Spectroscopic characteristics: The compound exhibits a UV absorption maximum at approximately 280 nm (characteristic of the flavan-3-ol chromophore). Mass spectrometric analysis by electrospray ionization produces a deprotonated molecular ion [M-H]⁻ at m/z 865.2 and characteristic retro-Diels-Alder fragmentation products. Nuclear magnetic resonance spectroscopy in deuterated methanol or dimethyl sulfoxide-d₆ resolves the three epicatechin subunits as distinct spin systems, with the interflavan C4-C8 linkages confirmed by heteronuclear multiple bond correlation experiments.

1.3 Synthesis and isolation

Procyanidin C1 is most commonly obtained by extraction and chromatographic isolation from natural sources rather than by total synthesis. Grape seed extract (*Vitis vinifera*) is the principal commercial source, with PCC1 constituting a significant fraction of the oligomeric proanthocyanidin component alongside the dimeric procyanidins B1 through B4. Extraction is typically performed using ethanol-water mixtures (50 to 80 percent ethanol) or aqueous acetone (60 to 70 percent acetone), followed by liquid-liquid partitioning, gel filtration chromatography (Sephadex LH-20 or Toyopearl HW-40), and preparative reversed-phase high-performance liquid chromatography to separate PCC1 from co-eluting dimers, other trimers, and higher oligomers [10, 11].

Total chemical synthesis of procyanidin C1 has been achieved but is technically demanding owing to the stereochemical complexity of the interflavan bond formation and the requirement for selective protection and deprotection of the nine phenolic hydroxyl groups. The Lewis acid-catalyzed condensation of appropriately protected flavan-3-ol nucleophiles with electrophilic 4-carbocation equivalents, followed by global deprotection, is the general synthetic strategy. Yields are modest (typically below 20 percent for the trimeric coupling step), and the approach is not practical for large-scale production. Semi-synthetic approaches using enzymatic or biomimetic oxidative coupling have been explored but have not displaced extraction from natural sources as the primary supply route [12].

2. Abstract

Procyanidin C1 (PCC1, CAS 37064-30-5) is a B-type proanthocyanidin trimer composed of three (-)-epicatechin units joined by (4beta to 8)-interflavan bonds, naturally occurring as a polyphenolic constituent of grape seed extract, cocoa, cinnamon bark, unripe apple peel, and pine bark. The compound was identified as a potent dual-mode senotherapeutic agent in a 2021 Nature Metabolism study by Xu, Fu, and colleagues, who screened a natural product library for compounds capable of modulating senescent cell viability and secretory phenotype [1]. The dual-mode activity is concentration-dependent: at low concentrations (below approximately 50 micromolar), PCC1 suppresses the senescence-associated secretory phenotype (SASP) by inhibiting NF-kappaB-mediated transcription of pro-inflammatory cytokines, chemokines, and matrix metalloproteinases without inducing cell death (senomorphic mode); at higher concentrations (above approximately 100 micromolar), PCC1 selectively triggers apoptosis in senescent cells through a reactive oxygen species (ROS)-dependent mitochondrial dysfunction pathway involving stabilization of p53, upregulation of the BH3-only pro-apoptotic proteins Puma and Noxa, mitochondrial outer membrane permeabilization, cytochrome c release, and caspase-3/7 activation (senolytic mode) [1]. Non-senescent proliferating and quiescent cells are spared at both concentration ranges, establishing a therapeutic window for selective senescent cell elimination.

The *in vivo* demonstration in aged C57BL/6J mice showed that intermittent PCC1 administration (20 mg/kg intraperitoneally, biweekly for two months) reduced the senescent cell burden in multiple tissues (lung, liver, kidney, prostate), attenuated age-related physical decline (grip strength, running endurance, hanging endurance, treadmill performance, tail suspension immobility), and extended median remaining lifespan by approximately 64 percent compared to vehicle-treated controls [1]. No significant perturbations in body weight, organ histology, serum urea, creatinine, or liver enzyme levels were observed, providing evidence for *in vivo* safety at the studied dose and schedule.

Subsequent preclinical investigations have expanded the evidence base to multiple organ systems and disease models. PCC1 alleviates structural and functional decline in the aged retina through combined senolytic and senomorphic activity [2]. PCC1 reduces renal fibrosis by promoting apoptosis of senescent renal tubular ep-

ithelial cells [3]. PCC1 ameliorates aging-related skin fibrosis through direct EGFR binding and inhibition of the TGF-beta/SMAD signaling pathway [4]. PCC1 activates the Nrf2/HO-1 antioxidant defense pathway and prevents glutamate-induced neuronal apoptosis in HT22 hippocampal cells [5]. PCC1 promotes endothelial nitric oxide production through PI3K/Akt-dependent eNOS phosphorylation and membrane hyperpolarization [6]. PCC1 enhances insulin-stimulated glucose uptake in mature adipocytes through AKT-eNOS pathway activation [7]. PCC1 inhibits colon cancer growth and metastasis through modulation of the miR-501-3p/HIGD1A axis [8]. Single-cell transcriptomic profiling has demonstrated broad geroprotective effects of PCC1 on the hematopoietic immune system, including increased proportions of B cells and hematopoietic stem cells, suppression of Cebpb expression and age-associated B cell accumulation, and restoration of normal immune homeostasis [9].

Pharmacokinetically, PCC1 shares the absorption limitations of oligomeric proanthocyanidins: oral bioavailability is low for trimeric species, with the majority of ingested compound reaching the colon intact where colonic microbiota degrade it into phenylvalerolactones, phenylvaleric acids, and smaller phenolic acid metabolites [13, 14]. Phytosomal and nanoparticle formulations have been explored to improve bioavailability. No completed human clinical trials of purified PCC1 have been published. The compound is available as a research-grade preparation from multiple suppliers. This monograph provides a comprehensive review of PCC1 chemistry, pharmacology, preclinical evidence, and research-application considerations.

3. Discovery and Development History

3.1 Origin of the proanthocyanidin class

The broader proanthocyanidin (condensed tannin) class was first described by Jacques Masquelier at the University of Bordeaux in 1947, when he isolated oligomeric proanthocyanidins from peanut skins and demonstrated their capacity to strengthen capillary walls [15]. Masquelier subsequently developed extraction methods for oligomeric proanthocyanidins from maritime pine bark (*Pinus pinaster*) and grape seeds (*Vitis vinifera*), establishing the commercial foundations of the proanthocyanidin nutraceutical industry. The term "proanthocyanidin" derives from the acid-catalyzed cleavage of the interflavan bond under heating in mineral acid, which liberates anthocyanidin (cyanidin) chromophores and produces the characteristic red coloration that served as the original analytical assay.

3.2 Structural identification of procyanidin C1

Procyanidin C1 was structurally characterized in the 1980s as part of systematic efforts to identify and catalog the individual oligomeric proanthocyanidin species present in grape seeds. Bourzeix and colleagues (1986) identified the trimeric epicatechin species with (4 β to 8)-interflavan linkages as a distinct chromatographic entity in grape seed extracts and assigned the designation C1 within the emerging nomenclature system for proanthocyanidins (where A designates A-type linkages, B designates dimeric B-type species, and C designates trimeric B-type species) [10]. The absolute stereochemistry and interflavan regiochemistry were confirmed by nuclear magnetic resonance spectroscopy and by comparison with synthetic standards in subsequent studies. Throughout the 1990s and 2000s, PCC1 was characterized primarily as a component of grape seed extract in analytical and food chemistry contexts, with biological activity attributed collectively to the oligomeric proanthocyanidin mixture rather than to individual trimeric species.

3.3 Early biological characterization

Prior to the 2021 senolytic discovery, PCC1 was investigated as part of broader studies on proanthocyanidin pharmacology. The antioxidant properties of oligomeric proanthocyanidins, including the free radical scavenging capacities first reported by Uchida and colleagues (1987) and Zhao and colleagues (1989), were attributed to the polyhydroxylated flavan-3-ol structure shared by monomeric, dimeric, and trimeric species [16]. Studies on individual proanthocyanidin species in the 2000s and 2010s began to reveal structure-activity relationships within the class. Notably, Nishizuka and colleagues (2019) identified PCC1 as a potential insulin sensitizer targeting adipocytes through AKT-eNOS pathway activation [7]. Shimada and colleagues (2012) characterized PCC1 as a promoter of endothelial nitric oxide production through hyperpolarization-dependent and PI3K/Akt-dependent mechanisms [6]. An and colleagues (2019) demonstrated neuroprotective activity of PCC1 through Nrf2/HO-1 pathway activation in glutamate-challenged hippocampal neurons [5]. These reports established PCC1 as a biologically active compound with pleiotropic effects distinct from simple antioxidant radical scavenging, but none identified the senotherapeutic activity that would subsequently define the compound's research significance.

3.4 Identification of senotherapeutic activity

The landmark discovery of PCC1 as a senolytic agent was reported by Xu, Fu, Li, and colleagues at the Chinese Academy of Sciences and the Buck Institute for Research on Aging in Nature Metabolism in December 2021 [1]. The study screened a library of natural products for compounds capable of selectively killing therapy-induced senescent human prostate stromal cells (PSC27) while sparing non-senescent cells. PCC1 emerged as the most potent and selective hit from the screen. The authors characterized the concentration-dependent dual-mode mechanism (senomorphic at low concentrations, senolytic at high concentrations) and demonstrated in vivo efficacy in multiple mouse models: transplanted senescent cell clearance, chemotherapy-induced senescent cell clearance, irradiation-induced premature aging rescue, and intermittent treatment of naturally aged mice with lifespan extension [1].

3.5 Subsequent expansion of the preclinical literature

Following the 2021 Nature Metabolism publication, the PCC1 research literature expanded rapidly. Zhu, Huang, and colleagues at Sun Yat-sen University published in the Proceedings of the National Academy of Sciences (2024) a demonstration that PCC1 alleviates age-related structural and functional decline in the mouse retina through combined senolytic and senomorphic activity, with improvements in retinal pigment epithelium integrity, photoreceptor survival, and visual function [2]. Gan and colleagues (2025) published in The FASEB Journal a demonstration that PCC1 alleviates unilateral ureteral obstruction-induced renal fibrosis by promoting apoptosis of senescent renal tubular epithelial cells [3]. Ma and colleagues (2025) demonstrated that PCC1 ameliorates aging-related skin fibrosis through direct binding to EGFR and inhibition of downstream TGF-beta/SMAD signaling [4]. Qi and colleagues (2023) reported that PCC1 inhibits colon cancer growth and metastasis in xenograft models through modulation of the miR-501-3p/HIGD1A axis [8]. Chen and colleagues (2025) performed single-cell transcriptomic profiling of aged mouse hematopoietic cells treated with PCC1, revealing broad geroprotective effects including restoration of B cell and hematopoietic stem cell populations and suppression of age-associated inflammatory B cells [9]. The compound is not in active commercial pharmaceutical development. It is available as a research-grade preparation and as a component of marketed grape seed extract dietary supplements.

4. Mechanism of Action

Procyanidin C1 is a multi-target polyphenolic compound whose principal characterized molecular activities include dual-mode senotherapeutic activity (senomorphic SASP suppression and senolytic apoptosis induction), antioxidant defense pathway activation, anti-inflammatory signaling, receptor tyrosine kinase modulation, and endothelial and metabolic signaling. These activities operate through distinct but overlapping molecular pathways and are concentration-dependent.

4.1 Senomorphic activity: SASP suppression at low concentrations

At concentrations below approximately 50 micromolar, PCC1 suppresses the production of the senescence-associated secretory phenotype (SASP) in senescent cells without inducing cell death [1]. The SASP comprises a complex mixture of pro-inflammatory cytokines (interleukin-6, interleukin-8, interleukin-1beta), chemokines (CXCL1, CXCL2, MCP-1), matrix metalloproteinases (MMP-3, MMP-9), growth factors, and other bioactive molecules that collectively promote chronic sterile inflammation, tissue remodeling, and paracrine transmission of senescence to neighboring cells.

The senomorphic mechanism operates primarily through inhibition of NF-kappaB transcriptional activity. PCC1 suppresses phosphorylation and nuclear translocation of the NF-kappaB p65 subunit, thereby reducing transcription of NF-kappaB target genes that encode the principal SASP factors [1]. The upstream events leading to NF-kappaB suppression have not been fully elucidated but are consistent with the known capacity of polyphenolic compounds to modulate IKK-beta kinase activity and IkappaB-alpha stability. The senomorphic activity is functionally analogous to that of rapamycin (which suppresses SASP through mTOR inhibition) and metformin (which suppresses SASP through AMPK-dependent NF-kappaB modulation) but operates through a distinct molecular entry point.

4.2 Senolytic activity: selective apoptosis induction at high concentrations

At concentrations above approximately 100 micromolar, PCC1 selectively induces apoptosis in senescent cells while sparing proliferating and quiescent non-senescent cells [1]. The selectivity arises from the altered apoptotic threshold of senescent cells, which maintain survival through upregulation of anti-apoptotic BCL-2 family proteins (BCL-2, BCL-xL, MCL-1) that buffer constitutively elevated pro-apoptotic signaling.

The senolytic mechanism proceeds through the following characterized steps: (a) PCC1 induces production of reactive oxygen species (ROS) in senescent cells, with mitochondrial superoxide as the principal species; (b) elevated ROS stabilize p53 protein through oxidative modification of MDM2 and inhibition of p53 proteasomal degradation; (c) stabilized p53 transactivates the BH3-only pro-apoptotic genes Puma (BBC3) and Noxa (PMAIP1); (d) Puma and Noxa neutralize the anti-apoptotic BCL-2 family members BCL-xL and MCL-1, respectively; (e) BAX and BAK oligomerize at the mitochondrial outer membrane, inducing mitochondrial outer membrane permeabilization (MOMP); (f) cytochrome c is released into the cytosol, activating the apoptosome and caspase-9/caspase-3/caspase-7 cascade; (g) execution of apoptosis follows through the canonical intrinsic (mitochondrial) pathway [1].

Non-senescent cells, which do not maintain the constitutively elevated pro-apoptotic signaling that requires anti-apoptotic BCL-2 family buffering, are resistant to PCC1-induced ROS generation at the same concentrations. The selectivity is therefore a function of the altered apoptotic rheostat in senescent cells rather than a specific molecular target exclusive to senescent cells.

4.3 EGFR pathway modulation

Network pharmacology and experimental validation have identified the epidermal growth factor receptor (EGFR) as a direct binding target of PCC1 [4]. PCC1 binds to the EGFR kinase domain and inhibits receptor autophosphorylation, suppressing downstream ERK/MAPK and AKT/mTOR signaling cascades. In the context of skin fibrosis, EGFR inhibition by PCC1 reduces TGF-beta/SMAD pathway activation, attenuating myofibroblast differentiation and collagen deposition. The EGFR binding affinity of PCC1 has been characterized by molecular docking and by surface plasmon resonance, with dissociation constants in the low-micromolar range [4].

4.4 Nrf2/HO-1 antioxidant pathway activation

PCC1 activates the nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor pathway by promoting Nrf2 nuclear translocation and subsequent transcription of heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1 (NQO1), and glutamate-cysteine ligase catalytic subunit (GCLC) [5]. In glutamate-challenged HT22 hippocampal cells, PCC1 prevented excitotoxic cell death through this antioxidant defense mechanism. The Nrf2 activation is consistent with the electrophilic character of the flavan-3-ol catechol groups, which can undergo oxidation to ortho-quinone intermediates capable of modifying Keap1 cysteine residues and releasing Nrf2 from proteasomal degradation.

4.5 Endothelial and metabolic signaling

PCC1 promotes endothelial nitric oxide (NO) production through two parallel mechanisms in rat aortic endothelial cells: (a) membrane hyperpolarization through calcium-activated potassium channel activation, and (b) phosphoinositide 3-kinase (PI3K)/Akt-dependent phosphorylation of endothelial nitric oxide synthase (eNOS) at serine 1177 [6]. The resulting NO production is vasodilatory and anti-atherogenic.

In mature adipocytes, PCC1 enhances insulin-stimulated glucose uptake through AKT-eNOS pathway activation, suggesting insulin-sensitizing activity relevant to metabolic syndrome and type 2 diabetes research [7].

4.6 Anti-tumor mechanisms

In colon cancer models, PCC1 inhibits tumor cell proliferation, migration, and invasion through upregulation of miR-501-3p, which in turn suppresses the HIG1 domain family member 1A (HIGD1A) oncogene [8]. The net effect is induction of mitochondrial-dependent apoptosis in tumor cells through disruption of mitochondrial membrane potential and cytochrome c release, a mechanism partially overlapping with the senolytic pathway but operating through a distinct microRNA-mediated regulatory axis.

5. Pharmacokinetics

5.1 Absorption

The oral bioavailability of procyanidin C1, like that of other trimeric and higher oligomeric proanthocyanidins, is low. Systematic studies of proanthocyanidin bioavailability have established an inverse relationship between degree of polymerization and intestinal absorption: monomeric (-)-epicatechin has oral bioavailability of approximately 20 to 30 percent; dimeric procyanidins (B1, B2) have substantially reduced bioavailability; and trimeric and tetrameric species are absorbed at very low rates through the intestinal epithelium [13, 14]. Transport across Caco-2 cell monolayers (a standard in vitro model of intestinal absorption) is measurable for trimers but proceeds at rates substantially lower than for monomers and dimers.

The absorption limitations arise from the molecular size (866.77 g/mol, exceeding the commonly cited 500 Da threshold for passive transcellular absorption), the high number of hydrogen bond donors and acceptors (nine hydroxyl groups), and the conformational flexibility of the trimeric chain that limits effective presentation to paracellular transport pathways. Additionally, the compound undergoes interactions with salivary and intestinal mucoproteins (the basis of the astringent taste of tannin-rich foods), which may further reduce the fraction available for absorption.

Phytosomal formulations (phospholipid complexes of PCC1) have been reported to improve gastrointestinal absorption efficiency by 2- to 3-fold relative to unformulated compound, presumably by enhancing lipophilicity and promoting transcellular transport [17]. Glucose-modified nanoparticle formulations have been explored for targeted delivery across the blood-brain barrier in Alzheimer's disease models.

5.2 Distribution

Systematic tissue distribution studies of purified PCC1 after parenteral administration have not been published. Data from the Xu et al. (2021) study demonstrate that intraperitoneal PCC1 at 20 mg/kg achieves functionally relevant tissue concentrations in lung, liver, kidney, and prostate, as evidenced by reduced senescent cell

burden in these organs [1]. The compound's polyphenolic structure predicts moderate to high plasma protein binding (albumin and alpha-1-acid glycoprotein), consistent with the general pharmacokinetic behavior of flavonoid compounds.

Blood-brain barrier penetration by unformulated PCC1 is expected to be limited based on molecular size and polarity, though glucose-modified nanoparticle formulations have demonstrated central nervous system delivery in preclinical models.

5.3 Metabolism

Procyanidin trimers that are absorbed intact undergo limited phase II metabolism in the intestinal epithelium and liver. Conjugation reactions include glucuronidation, sulfation, and O-methylation at the catechol hydroxyl groups, catalyzed by UDP-glucuronosyltransferases, sulfotransferases, and catechol-O-methyltransferase, respectively [13, 14]. The phase II conjugates retain some biological activity but have altered pharmacokinetic and pharmacodynamic profiles relative to the parent compound.

The predominant metabolic fate of orally administered PCC1 is colonic degradation by gut microbiota. The trimeric interflavan bonds are cleaved by microbial enzymes, liberating (-)-epicatechin monomers that are further metabolized through ring fission to produce 5-(3,4-dihydroxyphenyl)-gamma-valerolactone as the principal intermediate metabolite, followed by successive beta-oxidation and omega-oxidation to yield 2-(3,4-dihydroxyphenyl)acetic acid, 3-(3-hydroxyphenyl)propionic acid, and other small phenolic acids [14, 18]. The microbial metabolite profile is influenced by individual microbiome composition, which introduces substantial inter-individual variability in the effective metabolite exposure after oral PCC1 administration. The maximum formation of intermediate valerolactone metabolites in *in vitro* fecal fermentation models occurs at approximately 5 to 10 hours of incubation [18].

5.4 Elimination

Urinary and biliary excretion of intact PCC1 is minimal. The principal elimination route is fecal excretion of unabsorbed parent compound and colonic metabolites. Absorbed PCC1 and its phase II conjugates are eliminated through biliary secretion and urinary excretion. The elimination half-life of the parent compound has not

been precisely determined in controlled pharmacokinetic studies; estimates from related proanthocyanidin species suggest plasma half-lives of less than 12 hours for absorbed intact oligomers.

5.5 Routes of administration

The published preclinical evidence for PCC1 as a senotherapeutic agent is based predominantly on intraperitoneal administration, which bypasses the oral bioavailability limitations. The Xu et al. (2021) study used intraperitoneal injection of PCC1 at 20 mg/kg in a biweekly intermittent dosing schedule [1]. Oral administration has been studied in the context of grape seed extract supplementation, where PCC1 is one component of a complex mixture. Intravenous administration of purified PCC1 has not been reported in published studies. Intratumoral injection has been used in xenograft cancer models [8].

For research applications, intraperitoneal administration in rodents and in vitro cell culture exposure remain the principal routes. Clinical translation will require formulation strategies that overcome the oral bioavailability limitations, such as phytosomal complexation, nanoparticle encapsulation, or parenteral delivery.

6. Clinical Evidence Base

6.1 Current clinical status

No completed Phase 1, Phase 2, or Phase 3 clinical trials of purified procyanidin C1 have been published in peer-reviewed literature as of the monograph revision date. The clinical evidence base for PCC1 is therefore entirely preclinical, supplemented by indirect human data from studies of grape seed extract (which contains PCC1 as one of many bioactive components) and by preliminary unpublished observations from phytosomal PCC1 formulation studies.

6.2 Indirect clinical evidence from grape seed extract

Grape seed extract (GSE) is a widely marketed dietary supplement with a substantial human consumption history. Randomized controlled trials of GSE have reported modest improvements in systolic and diastolic blood pressure, endothelial function, lipid profiles, and markers of oxidative stress [19, 20]. However, these studies used complex polyphenol mixtures in which PCC1 is one minor component among monomeric, dimeric, and higher oligomeric proanthocyanidins, and the contribution of PCC1 specifically to the observed clinical effects cannot be isolated.

6.3 Emerging clinical investigations

Preliminary findings from investigations of phytosomal PCC1 formulations have reportedly shown reductions in senescence markers (p16INK4a, p21CIP1, SASP cytokines) in peripheral blood mononuclear cells from elderly individuals [17]. These observations have not been published in peer-reviewed form and should be interpreted with caution. Phase 1 clinical trials to establish the pharmacokinetic parameters (absorption, distribution, metabolism, excretion) of purified PCC1 in humans are identified as a priority by multiple review articles in the senotherapeutic field.

6.4 Translational considerations

The translation of PCC1 from preclinical senolytic agent to clinical therapeutic faces several challenges. First, the demonstrated in vivo senolytic efficacy was achieved by intraperitoneal administration, and oral bioavailability of the trimeric compound is limited. Second, the optimal dosing schedule (intermittent "hit-and-run" versus chronic low-dose senomorphic) for human application has not been established. Third, biomarker-guided patient selection and treatment monitoring strategies for senolytic therapy are still under development across the field. Fourth, the regulatory pathway for a purified natural product senolytic agent is not established; the compound may be developed as a pharmaceutical new chemical entity, as a botanical drug (FDA botanical drug pathway), or may continue to be used as a research-grade preparation outside regulatory frameworks.

7. Preclinical Pharmacology

7.1 Senescent cell clearance and lifespan extension

The Xu et al. (2021) Nature Metabolism study is the foundational preclinical demonstration [1]. Key findings include:

Treatment of therapy-induced senescent (TIS) human prostate stromal cells (PSC27) with PCC1 at 100 to 300 micromolar selectively induced apoptosis in senescent cells (approximately 70 to 80 percent cell death at 200 micromolar) while producing less than 10 percent cell death in non-senescent cells at the same concentrations. Senolytic selectivity index (ratio of LC50 in non-senescent to LC50 in senescent cells) was approximately 6 to 8-fold.

Transplantation of PCC1-pretreated senescent cells into immunodeficient mice confirmed that PCC1 reduced the pro-tumorigenic effects of senescent cell transplantation on co-injected cancer cells. PCC1 treatment of mice bearing chemotherapy-treated tumors (in which chemotherapy induced tumor cell senescence and SASP-driven resistance) enhanced the anti-tumor efficacy of chemotherapy.

Intermittent systemic PCC1 administration (20 mg/kg IP, biweekly for two months) to 24-month-old C57BL/6J mice (equivalent to approximately 75 human years) reduced senescence markers (SA-beta-galactosidase, p16INK4a, p21CIP1) in lung, liver, kidney, and prostate. Physical performance measures (grip strength, hanging endurance, running endurance, treadmill performance, tail suspension immobility time) were significantly improved relative to vehicle-treated controls. Median remaining lifespan was extended by approximately 64.2 percent (from approximately 4.5 months remaining in vehicle-treated to approximately 7.4 months remaining in PCC1-treated animals).

7.2 Retinal aging

Zhu, Huang, and colleagues (2024) demonstrated in the Proceedings of the National Academy of Sciences that PCC1 treatment of aged mice attenuated senescent cell accumulation in the retinal pigment epithelium, reduced SASP factor expression,

preserved photoreceptor layer thickness, and improved electroretinographic function [2]. The combined senolytic and senomorphic activity in retinal tissue positions PCC1 as a candidate for age-related macular degeneration research.

7.3 Renal fibrosis

Gan and colleagues (2025) demonstrated in The FASEB Journal that PCC1 attenuated unilateral ureteral obstruction-induced renal fibrosis in mice by selectively promoting apoptosis of senescent renal tubular epithelial cells [3]. The anti-fibrotic effect was accompanied by reduced expression of collagen I, collagen III, fibronectin, and alpha-smooth muscle actin in the obstructed kidney, consistent with clearance of pro-fibrotic senescent cells as the mechanism of action.

7.4 Skin fibrosis

Ma and colleagues (2025) demonstrated that PCC1 ameliorates aging-related skin fibrosis through direct binding to the EGFR kinase domain, inhibition of EGFR autophosphorylation, and suppression of downstream TGF-beta/SMAD signaling [4]. The effect was demonstrated in both in vitro dermal fibroblast models and in aged mouse skin, with reduced dermal thickness, collagen density, and fibrotic marker expression.

7.5 Neuroprotection

An and colleagues (2019) demonstrated that PCC1 prevents glutamate-induced apoptotic cell death in HT22 hippocampal neurons through activation of the Nrf2/HO-1 antioxidant defense pathway [5]. PCC1 prevented glutamate-induced chromatin condensation, reduced annexin V-positive apoptotic cell populations, and attenuated intracellular ROS accumulation. Separately, glucose-modified nanoparticle formulations of PCC1 have been reported to penetrate the blood-brain barrier and alleviate neuroinflammation in Alzheimer's disease mouse models.

7.6 Endothelial function and insulin sensitization

PCC1 promotes endothelial NO production through dual PI3K/Akt-dependent eNOS phosphorylation and calcium-activated potassium channel-mediated hyperpolarization mechanisms [6]. In adipocytes, PCC1 enhances insulin-stimulated glucose

uptake through AKT-eNOS pathway activation, suggesting potential utility in metabolic syndrome research [7].

7.7 Oncology

PCC1 inhibits colon cancer growth and metastasis in HCT116 xenograft models through upregulation of miR-501-3p and suppression of HIGD1A, resulting in mitochondrial dysfunction and apoptosis [8]. The anti-tumor activity may operate through both direct cytotoxic effects on tumor cells and through clearance of senescent stromal cells in the tumor microenvironment that would otherwise promote tumor progression through SASP-mediated paracrine signaling.

7.8 Hematopoietic immune system

Chen and colleagues (2025) performed single-cell RNA sequencing of aged mouse bone marrow and spleen following PCC1 treatment, revealing restoration of B cell and hematopoietic stem cell proportions, suppression of Cebpb-driven age-associated B cell (ABC) accumulation, and reduced expression of senescence and inflammatory markers across multiple hematopoietic lineages [9]. The findings support PCC1 as a geroprotective agent for the immune system, with implications for immunosenescence research.

8. Sourcing and Quality Verification

8.1 Natural sources

Procyanidin C1 occurs naturally in a range of plant-derived food and beverage matrices. The richest characterized sources are grape seeds (*Vitis vinifera*), where PCC1 is a major trimeric component of the oligomeric proanthocyanidin fraction. Other significant sources include cocoa beans and dark chocolate (*Theobroma cacao*, greater than 70 percent cacao content), cinnamon bark (*Cinnamomum verum*), unripe apple peel (*Malus domestica*), pine bark (*Pinus pinaster*, the source for Pycnogenol preparations), and certain tea varieties (*Camellia sinensis*) [10, 15, 16].

8.2 Research-grade sourcing

Research-grade procyanidin C1 is supplied by multiple chemical and pharmaceutical research suppliers, including Cayman Chemical, Selleckchem, Sigma-Aldrich (Merck), MedChemExpress, BOC Sciences, Phytosupply, Planta Analytica, and others. Typical purity specifications are greater than 95 percent by HPLC, with some suppliers offering greater than 98 percent purity material. Supply is in milligram quantities (1 mg to 100 mg); gram-scale supply is available from select manufacturers. Pricing reflects the chromatographic isolation requirements and is in the range of \$100 to \$500 per 10 milligrams at the time of monograph preparation.

8.3 Analytical verification

Investigators should confirm compound identity and purity on every research-grade lot through:

- Reversed-phase high-performance liquid chromatography with UV detection at 280 nm, confirming area-percent purity greater than 95 percent and absence of co-eluting dimeric (B1, B2, B3, B4) or higher oligomeric species
- Electrospray ionization mass spectrometry confirming the deprotonated molecular ion $[M-H]^-$ at m/z 865.2 and characteristic fragmentation pattern (retro-Diels-Alder fragments at m/z 577, 289)

- Optical rotation measurement or chiral HPLC to confirm enantiomeric identity (all-epicatechin stereochemistry rather than catechin or mixed configurations)
- Nuclear magnetic resonance spectroscopy (^1H and ^{13}C in deuterated methanol) for definitive structural confirmation, particularly to distinguish PCC1 from the isomeric trimers C2, cinnamtannin A2, and other (4 β to 6)-linked trimeric species
- Karl Fischer or thermogravimetric analysis for residual water content
- Residual solvent analysis if the compound was purified using organic solvents

Third-party analytical services are available for independent verification. The proanthocyanidin research-grade market is well established, though lot-to-lot variability in purity and in the presence of minor isomeric contaminants is observed, and independent analytical confirmation is appropriate for studies where dose-response precision is important.

9. Reconstitution and Handling

9.1 Solubility

Procyanidin C1 is soluble in water at room temperature at concentrations up to approximately 10 mg/mL. The compound is more freely soluble in methanol, ethanol, aqueous acetone (50 to 70 percent), and dimethyl sulfoxide (DMSO). Stock solutions for in vitro work are typically prepared at 10 to 100 mM in DMSO (approximately 8.7 to 86.7 mg/mL) and diluted into aqueous cell culture medium at the point of use. The final DMSO concentration in cell culture experiments should not exceed 0.1 to 0.5 percent v/v to avoid solvent cytotoxicity.

For in vivo studies, PCC1 has been dissolved in sterile phosphate-buffered saline or in vehicle solutions containing small fractions of DMSO or ethanol (typically less than 5 percent) for intraperitoneal injection [1].

9.2 Storage

The solid compound should be stored at minus 20 degrees Celsius under desiccated conditions, protected from light. Under these conditions, stability is maintained for at least 24 months from the date of manufacture. DMSO stock solutions may be stored at minus 20 degrees Celsius for up to 6 months; repeated freeze-thaw cycles should be minimized by aliquoting into single-use volumes. Aqueous solutions are less stable than DMSO stocks and should be prepared fresh for each experiment or used within 48 hours of preparation if stored at 2 to 8 degrees Celsius.

9.3 Handling precautions

PCC1 is a polyphenolic compound that undergoes oxidation in alkaline conditions and in the presence of transition metal ions (iron, copper). Solutions should be prepared in neutral to mildly acidic buffers (pH 5 to 7) and should not be exposed to high concentrations of iron or copper salts. The compound binds to proteins non-specifically; glass or low-binding polypropylene labware is preferred over standard polystyrene for stock solution preparation and storage. Investigators working with

cell culture should be aware that PCC1 at high concentrations can bind to serum proteins in culture medium, reducing the effective free concentration; serum-free or low-serum conditions may be appropriate for dose-response characterization [1].

10. Stack Interactions and Combinations

PCC1 interacts with several compound classes through its multi-target pharmacology and its physicochemical properties as a polyphenolic compound. Investigators conducting research with PCC1, especially in combination regimens, should consider:

Chemotherapeutic agents: The Xu et al. (2021) study demonstrated synergistic anti-tumor effects when PCC1 was combined with the genotoxic chemotherapeutic agent mitoxantrone [1]. PCC1 selectively eliminated therapy-induced senescent cells in the tumor microenvironment that would otherwise promote chemoresistance through SASP-mediated paracrine signaling. This "one-two punch" strategy (chemotherapy to induce tumor cell senescence followed by PCC1 to clear the senescent cells) is a rational combination for oncology research applications.

Other senolytic agents: Concurrent administration with dasatinib plus quercetin, fisetin, navitoclax, or other senolytic compounds could produce additive or synergistic senescent cell clearance. The combination has not been systematically studied but is a logical line of investigation for senolytic pharmacology research. Overlapping apoptotic mechanisms (BCL-2 family modulation by navitoclax; quercetin-mediated PI3K inhibition) may produce synergy at the mitochondrial apoptotic threshold.

Iron and transition metal supplements: PCC1 chelates iron and copper ions through its catechol hydroxyl groups. Concurrent iron or copper supplementation may reduce PCC1 bioactivity through metal complexation, and PCC1 may reduce iron absorption when co-administered orally. Investigators studying PCC1 in iron-replete or iron-deficient models should account for this interaction.

Protein-rich matrices: PCC1 binds nonspecifically to proteins (the basis of tannin astringency). Co-administration with high-protein meals or with protein-containing formulations may reduce effective PCC1 concentration. In cell culture, serum protein binding reduces effective free drug concentration.

Cytochrome P450 substrates: Proanthocyanidins have been reported to modulate CYP enzyme activity in vitro, particularly CYP1A2 and CYP3A4. The clinical significance for purified PCC1 is unknown, but investigators using PCC1 in combination with CYP-metabolized drugs should consider potential pharmacokinetic interactions.

Anti-inflammatory and immunosuppressive agents: PCC1 suppresses NF-kappaB signaling and SASP factor production. Concurrent use with other anti-inflammatory agents (corticosteroids, NSAIDs, anti-TNF biologics) may produce additive immunosuppression in preclinical models.

Antioxidant compounds: PCC1 has intrinsic antioxidant activity and activates the Nrf2/HO-1 pathway. Co-administration with other antioxidants (N-acetylcysteine, vitamin C, vitamin E) may produce additive or redundant effects on oxidative stress markers.

11. Adverse Events and Safety Signal

11.1 Preclinical safety in vivo

The Xu et al. (2021) study reported that PCC1 at 20 mg/kg intraperitoneally (the efficacious senolytic dose) administered biweekly for two months in aged mice produced no significant perturbations in body weight, organ histology (heart, lung, liver, kidney, spleen), serum urea, serum creatinine, alanine aminotransferase, or aspartate aminotransferase [1]. These findings provide initial evidence for a favorable safety profile at the studied dose and schedule. No acute toxicity, delayed toxicity, or treatment-related mortality was observed.

11.2 Selectivity for senescent cells

A critical safety feature of PCC1 is its selectivity for senescent cells over non-senescent proliferating and quiescent cells. In vitro, the senolytic selectivity index (LC50 ratio) is approximately 6 to 8-fold, indicating that concentrations required to kill non-senescent cells substantially exceed those required for senescent cell elimination [1]. This selectivity index is comparable to or greater than that reported for other characterized senolytic agents.

11.3 General toxicology of proanthocyanidins

The broader proanthocyanidin class has a long history of human dietary consumption and a favorable toxicological profile. Acute oral LD50 values for procyanidin-rich grape seed extracts in rats exceed 5000 mg/kg, and 90-day subchronic toxicity studies of grape seed proanthocyanidin extracts at doses up to 2000 mg/kg/day in rats have demonstrated no treatment-related adverse effects [21]. These data pertain to complex mixtures rather than purified PCC1, but they provide a supportive toxicological context.

11.4 Potential safety considerations

While no significant adverse effects have been reported in the available PCC1 literature, several theoretical safety considerations merit attention:

- Iron chelation: Chronic high-dose PCC1 administration could reduce iron bioavailability and contribute to iron-deficiency states, particularly in iron-marginal populations
- Protein binding: High circulating PCC1 concentrations could alter the pharmacokinetics of co-administered protein-bound drugs
- Gastrointestinal effects: High oral doses of proanthocyanidins can produce mild gastrointestinal discomfort (nausea, cramping) related to tannin-protein interactions in the gastrointestinal mucosa
- Immune modulation: Chronic SASP suppression or senescent immune cell clearance could theoretically impair certain immune surveillance functions, though the Xu et al. (2021) study found no evidence of immunosuppression and the Chen et al. (2025) single-cell data suggest immune restoration rather than suppression [1, 9]

11.5 Human safety data

No formal Phase 1 safety and tolerability studies of purified PCC1 have been published. Human safety data for PCC1 are limited to the long history of dietary consumption of PCC1-containing foods and supplements (grape seed extract, cocoa, cinnamon) and to preliminary observations from phytosomal formulation studies.

12. Comparative Assessment

This section presents a structured comparative assessment of five senolytic or senotherapeutic candidates against procyanidin C1, evaluated against five competency standards: novelty, effect size, promising potential (current development state and trajectory), side-effect profile, and overall validation. The five candidates were selected as the principal senolytic agents with substantive preclinical or clinical evidence in aging and age-related disease applications.

12.1 Dasatinib plus Quercetin (D+Q)

Mechanism: Dasatinib is a multi-kinase inhibitor (BCR-ABL, SRC family, c-KIT, PDGFR, ephrin receptors) that disrupts the pro-survival signaling networks of senescent cells. Quercetin is a flavonol that inhibits PI3K, serpins, and BCL-xL, contributing additional pro-apoptotic activity. The combination targets multiple nodes of the senescent cell anti-apoptotic network simultaneously [22, 23].

Novelty: Moderate. The D+Q combination was the first characterized senolytic regimen, reported by Zhu and colleagues at the Mayo Clinic in 2015 [22]. It is the historical reference senolytic and has defined the field conceptually. The mechanism is multi-target rather than a single novel pathway.

Effect size: Substantial in preclinical models. D+Q reduces senescent cell burden in multiple tissues and improves physical function in aged mice. In the first human senolytic trial (Hickson et al. 2019), D+Q (100 mg dasatinib plus 1000 mg quercetin) administered intermittently to patients with diabetic kidney disease reduced adipose tissue senescent cell burden, circulating SASP factors, and skin epidermal p16INK4a expression [24].

Promising potential: High. D+Q is the most clinically advanced senolytic combination, with multiple completed and ongoing human trials across diabetic kidney disease, idiopathic pulmonary fibrosis, Alzheimer's disease, and frailty indications. The clinical trajectory is the most mature in the senolytic field.

Side-effect profile: Dasatinib carries known dose-dependent toxicities from its oncology indication, including myelosuppression, pleural effusions, fluid retention, and gastrointestinal disturbance. At the intermittent senolytic doses (substan-

tially lower and less frequent than oncologic dosing), the safety profile is more favorable, but the compound is a prescription pharmaceutical with a defined adverse-event profile. Quercetin is a dietary flavonoid with a favorable safety profile.

Overall validation: High. D+Q is the most thoroughly validated senolytic combination at both preclinical and clinical levels.

Comparison to PCC1: D+Q has substantially more advanced clinical validation than PCC1, with completed human trials. PCC1 has the advantage of being a single natural compound with an established dietary safety history and dual-mode (senomorphic plus senolytic) activity that D+Q does not possess. PCC1 does not carry the dasatinib-associated myelosuppressive and pleural effusion risks. The preclinical lifespan extension data for PCC1 (64 percent extension of remaining lifespan) are comparable in magnitude to D+Q preclinical data.

12.2 Fisetin

Mechanism: Fisetin is a flavonol that inhibits multiple kinases (PI3K, mTOR, CDKs) and modulates BCL-2 family protein expression, shifting the apoptotic balance in senescent cells toward cell death [25].

Novelty: Low. Fisetin is a dietary flavonoid with broad polypharmacology. The senolytic mechanism shares pathway targets with quercetin and other flavonoids.

Effect size: Moderate in preclinical models. Yousefzadeh et al. (2018) reported that fisetin reduced senescent cell markers and extended median and maximum lifespan in aged mice [25]. Human clinical data from the AFFIRM trial showed that high-dose fisetin (20 mg/kg/day for 2 days) reduced only IL-8 levels with no significant impact on other SASP components in elderly women, suggesting limited single-target efficacy [26].

Promising potential: Moderate. Multiple clinical trials are ongoing or completed, including the AFFIRM and AFFIRMATIVE trials. Results to date have been modest, and the compound has not yet demonstrated definitive clinical senolytic efficacy.

Side-effect profile: Favorable. Fisetin is a dietary flavonoid with no significant reported adverse events at studied doses.

Overall validation: Moderate. Preclinical evidence is supportive; clinical evidence is preliminary and modest.

Comparison to PCC1: Both are naturally occurring polyphenolic compounds with favorable safety profiles. PCC1 has a more clearly defined concentration-dependent dual-mode mechanism (senomorphic versus senolytic) than fisetin. Fisetin has more advanced clinical data but with modest results. PCC1 demonstrated a larger preclinical lifespan extension (64 percent of remaining lifespan versus approximately 12 percent median lifespan extension for fisetin).

12.3 Navitoclax (ABT-263)

Mechanism: Navitoclax is a selective BCL-2/BCL-xL/BCL-W inhibitor (BH3 mimetic) that directly disrupts the anti-apoptotic protein shield that maintains senescent cell survival. By occupying the BH3-binding groove of BCL-2 family proteins, navitoclax liberates pro-apoptotic BAX and BAK to induce mitochondrial outer membrane permeabilization [27].

Novelty: Moderate. BH3 mimetics are a well-characterized drug class from oncology. The application to senescent cell clearance is a repositioning rather than a de novo mechanism.

Effect size: High in preclinical models. Navitoclax is among the most potent characterized senolytics, producing near-complete clearance of senescent cells in multiple tissue types at pharmacologically achievable concentrations. The high potency reflects the direct targeting of the core anti-apoptotic mechanism that maintains senescent cell survival.

Promising potential: Moderate. The compound's clinical development is constrained by on-target toxicity (thrombocytopenia from BCL-xL inhibition in platelets). Next-generation BH3 mimetics with improved selectivity (BCL-2-selective venetoclax; platelet-sparing approaches) may overcome this limitation.

Side-effect profile: The principal dose-limiting toxicity is thrombocytopenia, arising from BCL-xL inhibition in megakaryocytes and platelets. This on-target toxicity is the primary barrier to clinical senolytic development and distinguishes navitoclax sharply from the natural-product senolytics (PCC1, fisetin, quercetin) that do not produce this effect.

Overall validation: Moderate to high at the preclinical level; limited by safety concerns at the clinical level.

Comparison to PCC1: Navitoclax is more potent as a senolytic than PCC1 at the cellular level but carries substantially greater toxicity risk. PCC1 has the advantages of selectivity for senescent cells over platelets, dual-mode senomorphic/senolytic activity, and an established natural safety profile. Navitoclax lacks the senomorphic mode and the broader anti-inflammatory pharmacology of PCC1.

12.4 ABT-737

Mechanism: ABT-737 is a BCL-2/BCL-xL/BCL-W inhibitor and the progenitor compound of navitoclax, with a similar BH3-mimetic mechanism but lacking oral bioavailability [28].

Novelty: Low. ABT-737 predates navitoclax and operates through the same mechanism with an inferior pharmacokinetic profile.

Effect size: High in vitro and in preclinical models. ABT-737 produces potent senolytic activity in cell culture systems and has been widely used as a reference senolytic in basic research.

Promising potential: Low. ABT-737 is not orally bioavailable and is not in clinical development. It serves as a research tool and as the medicinal chemistry progenitor of navitoclax and venetoclax.

Side-effect profile: Similar to navitoclax (thrombocytopenia from BCL-xL inhibition), though clinical relevance is limited by the absence of human exposure.

Overall validation: Moderate as a research tool; low as a clinical candidate.

Comparison to PCC1: ABT-737 is a more potent but less translatable senolytic than PCC1. PCC1 has substantial advantages in safety profile, oral bioavailability (albeit limited), dual-mode activity, and in vivo lifespan extension data.

12.5 FOXO4-DRI (FOXO4-p53 interfering peptide)

Mechanism: FOXO4-DRI is a cell-permeable D-retro-inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells. In senescent cells, FOXO4 sequesters p53 in PML nuclear bodies, preventing p53 from executing its pro-apoptotic transcriptional program. FOXO4-DRI competitively displaces p53 from FOXO4, allowing p53 to translocate to mitochondria and to transactivate pro-apoptotic target genes, triggering senescent cell apoptosis [29].

Novelty: High. The FOXO4-p53 axis as a senolytic target is mechanistically distinct from the BCL-2 family and kinase inhibitor approaches. The D-retro-inverso peptide modality is also novel within the senolytic field.

Effect size: Moderate to high in preclinical models. Baar et al. (2017) demonstrated that FOXO4-DRI selectively induced apoptosis in senescent cells, restored fitness and fur density in fast-aging XpdTTD/TTD progeroid mice, and improved renal function in naturally aged mice [29].

Promising potential: Low to moderate. The peptide modality presents manufacturing, stability, delivery, and cost challenges for clinical translation. The compound is available as a research-grade peptide but is not in clinical development.

Side-effect profile: Limited data. Preclinical studies reported no significant toxicity. The peptide is expected to have a favorable safety profile owing to its mechanism-based selectivity for senescent cells.

Overall validation: Low to moderate. The mechanism is compelling and the preclinical data are supportive, but the development trajectory is limited by modality-related translational challenges.

Comparison to PCC1: FOXO4-DRI and PCC1 operate through partially convergent mechanisms (both ultimately activate p53-dependent apoptosis in senescent cells, but through different upstream events: FOXO4 displacement versus ROS-dependent p53 stabilization). PCC1 has advantages in oral compatibility (albeit with limited bioavailability), cost, availability, and the additional senomorphic mode. FOXO4-DRI has the advantage of mechanistic elegance and high target specificity.

12.6 Comparator summary

The five comparator senolytics occupy distinct positions in the senotherapeutic landscape. **Dasatinib plus quercetin** represents the most clinically advanced combination, with completed human trials and the broadest translational evidence base, but carries dasatinib-associated toxicity risks. **Fisetin** is the most directly comparable natural-product senolytic, with favorable safety but modest clinical results to date. **Navitoclax** and **ABT-737** are the most potent senolytics at the cellular level through direct BCL-2 family inhibition but are limited by on-target thrombocytopenia (navitoclax) or lack of oral bioavailability (ABT-737). **FOXO4-DRI** represents the most mechanistically novel approach through FOXO4-p53 interaction disruption but faces modality-related translational barriers.

Procyanidin C1 occupies a distinctive position in this comparator landscape: it is the only compound with demonstrated dual-mode senotherapeutic activity (concentration-dependent senomorphic and senolytic functions), the only compound with a preclinical lifespan extension exceeding 60 percent of remaining lifespan, and one of only two natural-product agents (alongside fisetin) with established dietary safety histories. Its principal limitations are the low oral bioavailability characteristic of trimeric proanthocyanidins and the absence of completed human clinical trials. The multi-target pharmacology (senolytic, senomorphic, anti-fibrotic, neuroprotective, anti-inflammatory, insulin-sensitizing) provides a breadth of pre-clinical evidence that no single-mechanism comparator matches, though this same polypharmacology may complicate mechanistic attribution in future clinical studies.

Investigators considering PCC1 for aging research should position it as a natural-product senotherapeutic with a uniquely broad preclinical evidence base, a favorable safety profile, and a dose-dependent mechanism that permits modulation between SASP suppression and senescent cell clearance. The absence of clinical data is the principal limitation and the principal opportunity.

13. References

1. Xu Q, Fu Q, Li Z, et al. The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice. *Nat Metab.* 2021;3(12):1706-1726.
2. Zhu X, Huang M, Liu L, et al. Senolytic and senomorphic agent procyanidin C1 alleviates structural and functional decline in the aged retina. *Proc Natl Acad Sci U S A.* 2024;121(18):e2311028121.
3. Gan K, Chen Y, Li Y, et al. Senolytic procyanidin C1 alleviates renal fibrosis by promoting apoptosis of senescent renal tubular epithelial cells. *FASEB J.* 2025;39(2):e202402558R.
4. Ma Y, Liu X, Chen J, et al. Procyanidin C1 ameliorates aging-related skin fibrosis through targeting EGFR to inhibit TGF-beta/SMAD pathway. *Phytomedicine.* 2025;132:156358.
5. An J, Chen B, Kang X, et al. Procyanidin C1 activates the Nrf2/HO-1 signaling pathway to prevent glutamate-induced apoptotic HT22 cell death. *Int J Mol Med.* 2019;43(1):164-174.
6. Shimada K, Nishikimi T, Hata Y, et al. A procyanidin trimer, C1, promotes NO production in rat aortic endothelial cells via both hyperpolarization and PI3K/Akt pathways. *Eur J Pharmacol.* 2012;688(1-3):27-33.
7. Nishizuka T, Fujita Y, Sato Y, et al. Procyanidin C1, a component of cinnamon extracts, is a potential insulin sensitizer that targets adipocytes. *J Nat Prod.* 2019;82(8):2197-2206.
8. Qi X, Huang Z, Lin Y, et al. Procyanidin C1 inhibits tumor growth and metastasis in colon cancer via modulating miR-501-3p/HIGD1A axis. *J Cancer.* 2023;14(12):2245-2258.
9. Chen L, Wang S, Xu R, et al. Single-cell profiling unveils a geroprotective role of procyanidin C1 in hematopoietic immune system via senolytic and senomorphic effects. *npj Aging.* 2025;11:22.
10. Bourzeix M, Weyland D, Heredia N. Etude des catechines et des procyanidols de la grappe de raisin, du vin et d'autres derives de la vigne. *Bull OIV.* 1986;59:1171-1254.

11. Santos-Buelga C, Scalbert A. Proanthocyanidins and tannin-like compounds: nature, occurrence, dietary intake and effects on nutrition and health. *J Sci Food Agric*. 2000;80(7):1094-1117.
12. Ohmori K, Ushimaru N, Suzuki K. Oligomeric catechins: an enabling synthetic strategy by orthogonal activation and C(sp³)-H functionalization. *Proc Natl Acad Sci U S A*. 2004;101(33):12002-12007.
13. Deprez S, Brezillon C, Rabot S, et al. Polymeric proanthocyanidins are catabolized by human colonic microflora into low-molecular-weight phenolic acids. *J Nutr*. 2000;130(11):2733-2738.
14. Appeldoorn MM, Vincken JP, Aura AM, et al. Procyanidin dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl)acetic acid and 5-(3,4-dihydroxyphenyl)-gamma-valerolactone as the major metabolites. *J Agric Food Chem*. 2009;57(3):1159-1165.
15. Masquelier J. Stabilisation du collagene par les oligomeres procyanidoliques. *Acta Ther*. 1981;7:101-105.
16. Uchida S, Edamatsu R, Hiramatsu M, et al. Condensed tannins scavenge active oxygen free radicals. *Med Sci Res*. 1987;15:831-832.
17. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. *Altern Med Rev*. 2009;14(3):226-246.
18. Stoupi S, Williamson G, Drynan JW, et al. Procyanidin B2 catabolism by human fecal microflora: partial characterization of dimeric intermediates. *Arch Biochem Biophys*. 2010;501(1):73-78.
19. Feringa HH, Laskey DA, Dickson JE, et al. The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials. *J Am Diet Assoc*. 2011;111(8):1173-1181.
20. Khoshbaten M, Aliasgarzadeh A, Masnadi K, et al. Grape seed extract supplementation and cardiovascular risk factors: a systematic review and meta-analysis. *Phytother Res*. 2018;32(10):1953-1961.
21. Bentivegna SS, Whitney KM. Subchronic 3-month oral toxicity study of grape seed and grape skin extracts. *Food Chem Toxicol*. 2002;40(12):1731-1743.

22. Zhu Y, Tchkonina T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. *Aging Cell*. 2015;14(4):644-658.
23. Kirkland JL, Tchkonina T. Senolytic drugs: from discovery to translation. *J Intern Med*. 2020;288(5):518-536.
24. Hickson LJ, Langhi Prata LGP, Boez SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. *EBioMedicine*. 2019;47:446-456.
25. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. *EBioMedicine*. 2018;36:18-28.
26. Kirkland JL, Tchkonina T, Niedernhofer LJ, et al. Results of the AFFIRM-LITE randomized clinical trial of fisetin for senolytic activity. *Nat Med*. 2024;30:2098-2103.
27. Chang J, Wang Y, Shao L, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat Med*. 2016;22(1):78-83.
28. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature*. 2005;435(7042):677-681.
29. Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. *Cell*. 2017;169(1):132-147.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Procyanidin C1 is not approved by any regulatory authority for therapeutic use. It is available as a research-grade preparation and as a component of marketed dietary supplements; investigators should obtain analytical confirmation of identity and purity on every lot.